Skip to main content
PH

Pelican Health

Pelican Health develops a medical device that utilizes advanced sampling techniques to collect and analyze microbiome data from patients. This technology enables healthcare providers to gain insights into gut health, which can inform treatment decisions for various gastrointestinal disorders.

Grenoble, FranceFounded 2020211K+ followers
Updated 3 months ago

Funding

Funding not disclosed

Funding rounds are not available yet.

Founders

Product

Problem

Current methods for sampling the human intestinal microbiome, such as animal models and fecal analysis, have significant limitations in accurately representing in-situ conditions within the small intestine. Endoscopy, while effective, is invasive, costly, and impractical for large-scale use. These limitations hinder the development of effective diagnostic and therapeutic strategies for gastrointestinal disorders.

Solution

Pelican Health provides a non-invasive solution for precise microbiome sampling within the small intestine using a ingestible capsule. The Pelican Health Capsule allows for targeted sampling from specific locations, minimizing contamination risk and enabling accurate, large-scale microbiome collection. This technology facilitates advanced diagnostic and therapeutic strategies for improved gastrointestinal health and efficient treatment of related diseases. The capsule is comparable in size to a pharmaceutical pill and allows for multiple in-situ microbiome samplings through a simple oral intake.

Target Audience

The primary target audience includes researchers, clinicians, and pharmaceutical companies focused on gastrointestinal health, microbiome analysis, and the development of targeted therapies for related diseases.

Features

  • Non-invasive sampling method using an ingestible capsule
  • Precise targeting of specific locations within the small intestine
  • Minimized contamination risk during sample collection
  • Enables large-scale microbiome collection for research and diagnostics
  • Facilitates the identification of new biomarkers
  • Supports the isolation of new bacterial strains and associated metabolites
  • Capsule transit time of 24-48 hours
  • Demonstrated high sample quality and patient comfort in clinical studies
  • 100% biocompatible materials
This profile is AI-generated and may contain inaccuracies.